On October 19, 2016 Abbott (NYSE: ABT) financial results for the third quarter ended Sept. 30, 2016 (Press release, Abbott, OCT 19, 2016, View Source [SID1234515913]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Third-quarter worldwide sales of $5.3 billion increased 2.9 percent on a reported basis and 4.0 percent on an operational basis.
Reported diluted EPS from continuing operations under GAAP was a $(0.24) loss in the third quarter, primarily due to an adjustment of $(0.66) per share associated with Abbott’s equity investment in Mylan to reflect Mylan’s share price as of Sept. 30, 2016. Excluding specified items, adjusted diluted EPS from continuing operations was $0.59 in the third quarter, at the high end of the previous guidance range.
Abbott adjusted its full-year 2016 EPS guidance for continuing operations under GAAP to $0.59 to $0.61, and narrowed and raised at the mid-point its full-year 2016 adjusted EPS for continuing operations to $2.19 to $2.21, exceeding its initial guidance for the year.
In the third quarter, Abbott received U.S. FDA approval for its FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring system for healthcare professionals to use with their patients with diabetes; submitted for U.S. regulatory approval a consumer version of FreeStyle Libre, to be used by people with diabetes to self-monitor glucose levels; received U.S. FDA approval for AbsorbTM, the only fully dissolving heart stent; and received U.S. FDA approval for TECNIS Symfony intraocular lenses for the treatment of cataracts, the first and only extended depth of focus lenses for people with cataracts.
On Sept. 16, 2016, Abbott announced the sale of Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion. This transaction aligns with Abbott’s shaping of its portfolio, which has recently focused on developing leadership positions in cardiovascular devices and expanding diagnostics. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions, including regulatory approvals.
"Strong performance in Established Pharmaceuticals and Medical Devices led our sales growth this quarter," said Miles D. White, chairman and chief executive officer, Abbott. "We’re on track to deliver the financial commitments we set at the beginning of the year. We also had several key product launches and continued to take strategic actions to shape our business for long-term growth."
THIRD-QUARTER BUSINESS OVERVIEW
Following are sales by business segment and commentary for the third quarter and the first nine months of the year:
Total Company
($ in millions)
% Change vs. 3Q15
Sales 3Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total *
1,645
3,657
5,302
4.5
2.2
3.7
2.9
4.0
Nutrition
755
1,000
1,755
3.5
(5.7)
(4.1)
(2.0)
(1.0)
Diagnostics
362
851
1,213
4.1
5.3
6.0
5.0
5.4
Established Pharmaceuticals
—
1,012
1,012
n/a
5.3
9.0
5.3
9.0
Medical Devices
519
791
1,310
6.0
6.7
6.1
6.4
6.0
* Total Abbott Sales from continuing operations include Other Sales of $12 million.
% Change vs. 9M15
Sales 9M16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total *
4,831
10,689
15,520
3.5
1.3
5.9
2.0
5.2
Nutrition
2,224
2,942
5,166
3.8
(3.0)
1.6
(0.2)
2.5
Diagnostics
1,062
2,495
3,557
3.6
3.9
7.1
3.8
6.1
Established Pharmaceuticals
—
2,880
2,880
n/a
1.6
9.8
1.6
9.8
Medical Devices
1,520
2,359
3,879
2.8
4.1
5.6
3.6
4.5
* Total Abbott Sales from continuing operations include Other Sales of $38 million.
n/a = Not Applicable.
Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Third-quarter 2016 worldwide sales of $5.3 billion increased 2.9 percent on a reported basis, including an unfavorable 1.1 percent effect of foreign exchange, and increased 4.0 percent on an operational basis. Excluding the impact of Venezuelan operations, sales would have increased 4.5 percent on a reported basis and 5.6 percent on an operational basis.
International sales increased 2.2 percent on a reported basis and 3.7 percent on an operational basis in the third quarter. International operational growth was led by strong performance across Established Pharmaceuticals, Diagnostics and Medical Devices.
Nutrition
($ in millions)
% Change vs. 3Q15
Sales 3Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
755
1,000
1,755
3.5
(5.7)
(4.1)
(2.0)
(1.0)
Pediatric
414
553
967
4.3
(9.4)
(7.5)
(4.0)
(2.8)
Adult
341
447
788
2.6
(0.8)
0.6
0.6
1.4
% Change vs. 9M15
Sales 9M16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
2,224
2,942
5,166
3.8
(3.0)
1.6
(0.2)
2.5
Pediatric
1,242
1,664
2,906
5.0
(5.1)
(0.7)
(1.0)
1.6
Adult
982
1,278
2,260
2.3
(0.1)
4.7
0.9
3.7
Worldwide Nutrition sales decreased 2.0 percent on a reported basis in the third quarter, including an unfavorable 1.0 percent effect of foreign exchange, and decreased 1.0 percent on an operational basis.
Worldwide Pediatric Nutrition sales decreased 4.0 percent on a reported basis in the third quarter, including an unfavorable 1.2 percent effect of foreign exchange, and decreased 2.8 percent on an operational basis. During the quarter, Abbott introduced Similac Pro-Advance and Similac Pro-Sensitive, the first infant formulas in the U.S. with a human milk oligosaccharide that offers a unique immune-nourishing prebiotic. International sales declined 9.4 percent on a reported basis and 7.5 percent on an operational basis, driven by challenging market conditions in China, partially offset by continued strong performance in Latin America and Southeast Asia.
Worldwide Adult Nutrition sales increased 0.6 percent on a reported basis in the third quarter, including an unfavorable 0.8 percent effect of foreign exchange, and increased 1.4 percent on an operational basis. Operational sales growth in the quarter was led by growth of Ensure, Abbott’s complete and balanced nutrition brand.
Diagnostics
($ in millions)
% Change vs. 3Q15
Sales 3Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
362
851
1,213
4.1
5.3
6.0
5.0
5.4
Core Laboratory
220
757
977
7.6
5.0
5.7
5.6
6.1
Molecular
42
70
112
(9.6)
5.4
6.3
(0.8)
(0.3)
Point of Care
100
24
124
3.4
15.6
14.1
5.6
5.3
% Change vs. 9M15
Sales 9M16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
1,062
2,495
3,557
3.6
3.9
7.1
3.8
6.1
Core Laboratory
616
2,224
2,840
3.4
3.8
7.1
3.7
6.3
Molecular
140
199
339
(3.4)
1.9
5.2
(0.3)
1.5
Point of Care
306
72
378
7.6
13.3
13.6
8.6
8.7
Worldwide Diagnostics sales increased 5.0 percent on a reported basis in the third quarter, including an unfavorable 0.4 percent effect of foreign exchange, and increased 5.4 percent on an operational basis. During the quarter, Abbott unveiled its new suite of diagnostic instruments, AlinityTM, at the American Association for Clinical Chemistry conference. The Alinity suite includes new instruments for every area of the diagnostics market where Abbott competes and incorporates features deemed important to customers, including increased automation, higher volumes, faster results, smaller size and an improved user interface.
Core Laboratory Diagnostics sales increased 5.6 percent on a reported basis in the third quarter, including an unfavorable 0.5 percent effect of foreign exchange, and increased 6.1 percent on an operational basis. Operational sales growth in the quarter was led by continued share gains in the U.S. and internationally.
Molecular Diagnostics sales decreased 0.8 percent on a reported basis in the third quarter, including an unfavorable 0.5 percent effect of foreign exchange, and decreased 0.3 percent on an operational basis. As expected, continued strong growth in Abbott’s infectious disease testing business was offset primarily by the planned scale down of its genetics business.
Point of Care Diagnostics sales increased 5.6 percent on a reported basis in the third quarter, including a favorable 0.3 percent effect of foreign exchange, and increased 5.3 percent on an operational basis. Sales growth was led by continued adoption of Abbott’s i-STAT handheld system in the U.S. and international markets.
Established Pharmaceuticals
($ in millions)
% Change vs. 3Q15
Sales 3Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
—
1,012
1,012
n/a
5.3
9.0
5.3
9.0
Key Emerging Markets
—
747
747
n/a
7.0
12.2
7.0
12.2
Other
—
265
265
n/a
0.7
0.6
0.7
0.6
% Change vs. 9M15
Sales 9M16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
—
2,880
2,880
n/a
1.6
9.8
1.6
9.8
Key Emerging Markets
—
2,135
2,135
n/a
2.7
13.4
2.7
13.4
Other
—
745
745
n/a
(1.5)
—
(1.5)
—
Established Pharmaceuticals sales increased 5.3 percent on a reported basis in the third quarter, including an unfavorable 3.7 percent effect of foreign exchange, and increased 9.0 percent on an operational basis.
Key Emerging Markets include India, Russia, Brazil and China, along with several additional emerging markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these key geographies increased 7.0 percent on a reported basis and 12.2 percent on an operational basis. Operational sales growth was led by continued strong growth in India, which comprises more than 20 percent of Abbott’s Established Pharmaceuticals sales, as well as above-market growth in several countries throughout Latin America driven by commercial initiatives and locally relevant portfolio expansion.
Medical Devices
($ in millions)
% Change vs. 3Q15
Sales 3Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
519
791
1,310
6.0
6.7
6.1
6.4
6.0
Vascular
305
403
708
9.8
2.0
1.4
5.2
4.9
Diabetes Care
96
210
306
(2.2)
19.1
20.7
11.5
12.5
Medical Optics
118
178
296
3.7
4.8
1.7
4.4
2.5
Vascular Product Lines:
Coronary Devicesa)
201
336
537
4.8
—
(0.8)
1.8
1.2
Endovascularb)
76
66
142
4.6
13.7
14.3
8.6
8.9
a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters and other coronary products.
b) Includes vessel closure, carotid stents and other peripheral products.
% Change vs. 9M15
Sales 9M16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
1,520
2,359
3,879
2.8
4.1
5.6
3.6
4.5
Vascular
940
1,235
2,175
9.5
0.1
1.8
3.9
4.9
Diabetes Care
238
594
832
(18.6)
12.6
15.7
1.5
3.5
Medical Optics
342
530
872
4.2
4.9
4.6
4.6
4.4
Vascular Product Lines:
Coronary Devicesa)
597
1,039
1,636
4.5
(1.5)
—
0.6
1.6
Endovascularb)
226
194
420
7.5
9.0
11.7
8.2
9.4
a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters and other coronary products.
b) Includes vessel closure, carotid stents and other peripheral products.
Worldwide Medical Devices sales increased 6.4 percent on a reported basis in the third quarter, including a favorable 0.4 percent effect of foreign exchange, and increased 6.0 percent on an operational basis.
Worldwide sales of Vascular products increased 5.2 percent on a reported basis in the third quarter, including a favorable 0.3 percent effect of foreign exchange, and increased 4.9 percent on an operational basis. Sales growth in Vascular products was led by double-digit growth of MitraClip, Abbott’s device for the treatment of mitral regurgitation, as Abbott continues to build the market for this first-in-class device. Strong sales growth in Abbott’s Endovascular business was driven by vessel closure products and Supera, Abbott’s unique stent for the treatment of blockages in the leg. In the quarter, Abbott received U.S. FDA approval for Absorb, the only fully dissolving heart stent.
Worldwide Diabetes Care sales increased 11.5 percent on a reported basis in the third quarter, including an unfavorable 1.0 percent effect of foreign exchange, and increased 12.5 percent on an operational basis. International sales growth was driven by continued consumer uptake of FreeStyle Libre, Abbott’s revolutionary continuous glucose monitoring system that eliminates the need for finger-sticks. In September, Abbott received U.S. FDA approval for the FreeStyle Libre Pro system, which is designed to help healthcare professionals make better, customized treatment decisions for their patients – and at a significantly lower cost than other professional continuous glucose monitoring systems. During the quarter, Abbott submitted the consumer version of the FreeStyle Libre system for review by the U.S. FDA. The consumer version of the FreeStyle Libre system is designed to eliminate the need for routine finger-sticks and provides glucose data in a simple format that allows people with diabetes to better self-monitor their glucose levels.
Worldwide Medical Optics sales increased 4.4 percent on a reported basis in the third quarter, including a favorable 1.9 percent effect of foreign exchange, and increased 2.5 percent on an operational basis. Operational sales growth was driven by continued market uptake of cataract products in the premium intraocular lens segment. In the quarter, Abbott received U.S. FDA approval and launched its TECNIS Symfony intraocular lenses, the first and only lenses in the U.S. that provide a full range of continuous high-quality vision following cataract surgery.
ABBOTT NARROWS ITS FULL-YEAR EARNINGS-PER-SHARE GUIDANCE
Abbott is adjusting its projected earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) to $0.59 to $0.61 for the full year 2016.
Abbott forecasts net specified items for the full year 2016 of approximately $1.60 per share. Specified items include intangible amortization expense, the impact of the Venezuelan currency devaluation in the first quarter and an adjustment to the equity investment in Mylan in the third quarter, expenses associated with acquisitions, including bridge facility fees, charges related to cost reduction initiatives and other expenses and the recognition of deferred taxes associated with the pending sale of the Abbott Medical Optics business (AMO), partially offset by the favorable resolution of various tax positions from prior years.
Excluding specified items, Abbott is raising the mid-point and narrowing its full-year 2016 guidance range for earnings per share from continuing operations to $2.19 to $2.21, exceeding its initial guidance for the year.
ABBOTT DECLARES 371ST QUARTERLY DIVIDEND
On Sept. 15, 2016, the board of directors of Abbott declared the company’s quarterly dividend of $0.26 per share. Abbott’s cash dividend is payable Nov. 15, 2016, to shareholders of record at the close of business on Oct. 14, 2016.
Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.